Written on February 28, 2011 at 3:20 pm by

Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide For Type 2 Diabetes In Japan

Filed under Diabetes News {no comments}

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) confirmed that Takeda Pharmaceutical Company Limited’s applications for two additional indications for “NESINA®” (alogliptin), combination therapy with sulfonylurea and combination therapy with biguanide for type 2 diabetes, were approved by the Japanese Ministry of Health, Labour and Welfare…

Related Posts with Thumbnails

No tags for this post.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>


Follow us!

Follow diabeticmart on Twitter or Follow diabeticmart on FaceBook

Advertisement

Please Visit our Sponsor:

American Diabetes Wholesale - Free Shipping on Orders Over $100